NCT03020017View on ClinicalTrials.gov

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

September 6, 2018

Study Completion Date

August 19, 2020

Conditions
GliosarcomaRecurrent Glioblastoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Targeted Molecular Therapy

Given NU-0129 IV

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT03020017 - NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | Biotech Hunter | Biotech Hunter